Investors Shift to High Dividend Stocks Amid Market Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Should l Buy ABBV?
Source: CNBC
- Increased Appeal of Dividend Stocks: In Q1 2026, nearly $22 billion flowed into dividend exchange-traded funds, marking the highest inflow since Q2 2022, indicating a trend of investors seeking relative safety amid market volatility.
- Uneven Market Performance: While the S&P 500 hit a new high on Monday, the market has been rocky this year due to factors like the Iran war, oil prices, and AI disruptions, leading to heightened demand for dividend stocks among investors.
- Analyst-Recommended Stocks: Stocks in the iShares Core High Dividend ETF have received buy or overweight ratings from over 55% of analysts, with expected price targets showing at least 15% upside, highlighting strong investment potential.
- Individual Stock Performance Analysis: For instance, AbbVie boasts a 3.4% dividend yield with 74% of analysts rating it a buy, while PNC Financial Services and PPL also show promising growth prospects with dividend yields of 3.1%, attracting investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 202.780
Low
223.00
Averages
252.00
High
289.00
Current: 202.780
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie: A Healthcare Stock Worth Considering for Long-Term Investment
- Strong Product Line: AbbVie boasts 12 blockbuster drugs generating over $1 billion in revenue, with 2025 performance highlighting its robust competitive position in the healthcare sector, further solidifying its status as an industry leader.
- Substantial R&D Investment: Since 2013, AbbVie has invested over $85 billion in R&D, focusing on approximately 90 new therapies, with 60 in mid-to-late stage development, showcasing its potential for future growth and innovation.
- Stable Dividend Returns: AbbVie offers a dividend yield of 3.4%, with payouts increasing over 330% since 2013, reaching $6.92 per share in 2023, making it attractive for long-term investors seeking reliable income.
- Reasonable Valuation Levels: Although AbbVie’s P/E ratio stands at 14, slightly above its five-year average of 13, its first-quarter revenue growth of 12.4%, along with strong performances from Skyrizi and Rinvoq, indicates significant investment value.
See More
AbbVie's Strong Earnings Amid Competitive Threats
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion and reflecting a 12.4% year-over-year growth, indicating robust market performance and a solid financial foundation.
- Immunology Segment Dominance: AbbVie's key growth drivers, Skyrizi and Rinvoq, generated $17.6 billion and $8.3 billion in revenue last year, respectively, with Skyrizi's year-over-year growth rate reaching 49.9%, solidifying its market leadership.
- Rising Competitive Risks: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, posing a potential threat to Skyrizi, which typically achieves only 51%, leading to positive market reactions to Oruka's results.
- Diversified Growth Strategy: Despite competitive pressures, AbbVie has other growth drivers like Qulipta and Botox, and is developing new products to reduce reliance on its immunology business, maintaining long-term attractiveness and a strong dividend policy.
See More
AbbVie Faces Competition from New Drug Threat
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion with a year-over-year increase of 12.4%, indicating robust overall business health despite looming competitive pressures.
- Skyrizi's Market Position: Skyrizi holds over 45% of the U.S. biologic psoriasis market, generating $17.6 billion in revenue last year with a 49.9% year-over-year growth rate, solidifying its leadership in a highly competitive landscape.
- Emerging Competitive Threat: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, potentially surpassing Skyrizi's 51%, leading to positive market reactions for Oruka and downward pressure on AbbVie's stock.
- Diversified Growth Drivers: Despite competitive threats, AbbVie has other growth drivers such as Qulipta and Botox, along with a strong pipeline expected to yield new products, thereby reducing reliance on its immunology segment.
See More
Investors Shift to High Dividend Stocks Amid Market Volatility
- Increased Appeal of Dividend Stocks: In Q1 2026, nearly $22 billion flowed into dividend exchange-traded funds, marking the highest inflow since Q2 2022, indicating a trend of investors seeking relative safety amid market volatility.
- Uneven Market Performance: While the S&P 500 hit a new high on Monday, the market has been rocky this year due to factors like the Iran war, oil prices, and AI disruptions, leading to heightened demand for dividend stocks among investors.
- Analyst-Recommended Stocks: Stocks in the iShares Core High Dividend ETF have received buy or overweight ratings from over 55% of analysts, with expected price targets showing at least 15% upside, highlighting strong investment potential.
- Individual Stock Performance Analysis: For instance, AbbVie boasts a 3.4% dividend yield with 74% of analysts rating it a buy, while PNC Financial Services and PPL also show promising growth prospects with dividend yields of 3.1%, attracting investor interest.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
AbbVie: A Healthcare Stock Worth Considering for Long-Term Investment
- Strong Product Line: AbbVie boasts 12 blockbuster drugs generating over $1 billion in revenue, with 2025 performance highlighting its robust competitive position in the healthcare sector, further solidifying its status as an industry leader.
- Substantial R&D Investment: Since 2013, AbbVie has invested over $85 billion in R&D, focusing on approximately 90 new therapies, with 60 in mid-to-late stage development, showcasing its potential for future growth and innovation.
- Stable Dividend Returns: AbbVie offers a dividend yield of 3.4%, with payouts increasing over 330% since 2013, reaching $6.92 per share in 2023, making it attractive for long-term investors seeking reliable income.
- Reasonable Valuation Levels: Although AbbVie’s P/E ratio stands at 14, slightly above its five-year average of 13, its first-quarter revenue growth of 12.4%, along with strong performances from Skyrizi and Rinvoq, indicates significant investment value.
See More
AbbVie's Strong Earnings Amid Competitive Threats
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion and reflecting a 12.4% year-over-year growth, indicating robust market performance and a solid financial foundation.
- Immunology Segment Dominance: AbbVie's key growth drivers, Skyrizi and Rinvoq, generated $17.6 billion and $8.3 billion in revenue last year, respectively, with Skyrizi's year-over-year growth rate reaching 49.9%, solidifying its market leadership.
- Rising Competitive Risks: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, posing a potential threat to Skyrizi, which typically achieves only 51%, leading to positive market reactions to Oruka's results.
- Diversified Growth Strategy: Despite competitive pressures, AbbVie has other growth drivers like Qulipta and Botox, and is developing new products to reduce reliance on its immunology business, maintaining long-term attractiveness and a strong dividend policy.
See More
AbbVie Faces Competition from New Drug Threat
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion with a year-over-year increase of 12.4%, indicating robust overall business health despite looming competitive pressures.
- Skyrizi's Market Position: Skyrizi holds over 45% of the U.S. biologic psoriasis market, generating $17.6 billion in revenue last year with a 49.9% year-over-year growth rate, solidifying its leadership in a highly competitive landscape.
- Emerging Competitive Threat: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, potentially surpassing Skyrizi's 51%, leading to positive market reactions for Oruka and downward pressure on AbbVie's stock.
- Diversified Growth Drivers: Despite competitive threats, AbbVie has other growth drivers such as Qulipta and Botox, along with a strong pipeline expected to yield new products, thereby reducing reliance on its immunology segment.
See More
Investors Shift to High Dividend Stocks Amid Market Volatility
- Increased Appeal of Dividend Stocks: In Q1 2026, nearly $22 billion flowed into dividend exchange-traded funds, marking the highest inflow since Q2 2022, indicating a trend of investors seeking relative safety amid market volatility.
- Uneven Market Performance: While the S&P 500 hit a new high on Monday, the market has been rocky this year due to factors like the Iran war, oil prices, and AI disruptions, leading to heightened demand for dividend stocks among investors.
- Analyst-Recommended Stocks: Stocks in the iShares Core High Dividend ETF have received buy or overweight ratings from over 55% of analysts, with expected price targets showing at least 15% upside, highlighting strong investment potential.
- Individual Stock Performance Analysis: For instance, AbbVie boasts a 3.4% dividend yield with 74% of analysts rating it a buy, while PNC Financial Services and PPL also show promising growth prospects with dividend yields of 3.1%, attracting investor interest.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
